respiratory
COPD

Mixed results for biologic in eosinophilic COPD


A subgroup of patients with COPD may benefit from biologic therapies, results of two Phase III trials suggest, but the jury is out on exactly which patients will benefit the most. The METREX trial, presented at ERS and published in the NEJM found 100 mg subcutaneous mepolizumab (Nucala) every four weeks for 52 weeks when added to triple therapy ...

Already a member?

Enter your email to keep reading.


OR